Dyslipidemia is a medical condition characterized by abnormal levels of lipids, including cholesterol and triglycerides, in the blood. It plays a crucial role in the development of cardiovascular diseases, such as atherosclerosis and coronary artery disease. The condition arises when there is an imbalance in the production, utilization, or clearance of lipids, leading to elevated levels of LDL cholesterol, commonly referred to as "bad" cholesterol, and reduced levels of HDL cholesterol, known as "good" cholesterol. Dyslipidemia often results from a combination of genetic factors, lifestyle choices, and underlying health conditions. Poor dietary habits, lack of physical activity, and obesity contribute significantly to its onset. Timely detection and management of dyslipidemia are essential to reduce the risk of cardiovascular events. Lifestyle modifications, including a heart-healthy diet, regular exercise, and smoking cessation, are key components of managing dyslipidemia. In some cases, medications such as statins may be prescribed to help control lipid levels and mitigate cardiovascular risks. Regular monitoring and collaboration with healthcare professionals are crucial for individuals with dyslipidemia to effectively manage and maintain optimal lipid levels, promoting heart health and overall well-being.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation